Abstracts tagged "risk assessment"

Abstract Number: 1975 • ACR Convergence 2025
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL, ⁴UF Jacksonville, ponte vedra, FL
Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 0264 • ACR Convergence 2025
Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease
Mohamed Tharwat Hegazy, Rania Yacoub, Sarah Sheta, Rana Hussein Amin and Noha Khalil, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Vogt-Koyanagi-Harada disease (VKH) is a systemic disease that affects the central nervous system, ocular, and integumentary system. It causes bilateral granulomatous uveitis, dysacusia ranging…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 1979 • ACR Convergence 2025
Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
Julia Wajsberg¹, Dana Nachawati², Lenche Kostadinova³, Donald Anthony⁴ and Maya Mattar³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland, ³Louis Stolkes Cleveland VA, Cleveland, ⁴The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Methotrexate (MTX) is widely used in rheumatologic disease but carries hepatotoxic risk. Standard monitoring relies on measurement of alanine and aspartate aminotransferase (ALT and…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
Abstract Number: 0342 • ACR Convergence 2025
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Edgar Wiebe¹, Benjamin Kuntz², Angela Galindo Santos³, Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche², Andriko Palmowski², Gerhard Krönke⁴, Ralf Schmidmaier⁵, Kay Raum³ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 2007 • ACR Convergence 2025
Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Min Jung Kim¹, Sang Min Lee², Jun Seok Kim², Borim Ryu² and Kichul Shin³, ¹Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ²Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government–Seoul National University Hospital Boramae Medical Center, Seoul, Republic of Korea, ³Seoul National University, Seoul, South Korea
Background/Purpose: Long-term hyperuricemia is essential for the development of gout. However, only 9.9% of individuals with asymptomatic hyperuricemia (AHU) develop gout within 10 years. Identifying…
Abstract Number: 2685 • ACR Convergence 2025
Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
Rachel Elam¹, Jing Li², Angel Paul³, Emma Kersey⁴, gabriela Schmajuk⁵, William Leslie⁶ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, Berkeley, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Women with rheumatoid arthritis (RA) have 1.5- and 2-fold higher risk of major osteoporotic fracture (MOF: first of distal forearm, hip, humerus, or clinical…
Abstract Number: 0612 • ACR Convergence 2024
Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Nevin Hammam¹, Ahmed Elsaman², Esam Abualfadl³, Soha Senara⁴, Nada M. Gamal⁵, Mona H. Abd Elsamea⁵, Abdelhfeez Moshrif⁶, Samar Tharwat⁷, Osman Hammam⁸ and Tamer A Gheita⁹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; Qena/Luxor Hospitals, Qena, Egypt, Sohag, Egypt, ⁴Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Assiut, Egypt, ⁶Al-azhar university, Assiut, Egypt, ⁷Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁸Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a great heterogeneity and unpredictable flare. In managing patients with SLE, the diagnosis…
Abstract Number: 1505 • ACR Convergence 2024
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Sara Ferrigno¹, Elizabeth Arkema², Lina Marcela Diaz-Gallo³, Iva Gunnarsson⁴, Agneta Zickert⁴ and Elisabet Svenungsson⁵, ¹Department of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden, ³Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) patients have higher cardiovascular (CV) risk compared to the general population, with a standardized CV mortality rate of 2-3 and…
Abstract Number: 2326 • ACR Convergence 2024
Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
Michael Dreyfuss¹, Dan Riesel², Guy Shalev², Benjamin Getz³, Or Ramni², Yonatan Jenudi⁴, Dimid Duchovny², Daniel Underberger⁵, Shlomit Steinberg-Koch², Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²Predicta Med Analytics Ltd., Ramat Gan, Israel, ³CTO, Ramat Gan, Israel, ⁴[email protected], Ramat Gan, Israel, ⁵Predicta Med Analytics Ltd., Bridgeport, CT, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are associated with indolent and non-specific signs and symptoms, and often result in physical impairment and poorer…
Abstract Number: 0674 • ACR Convergence 2024
Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data
Sara Shahid¹, Tyson Barrett², Sonia Manocha¹ and Tanmayee Bichile¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ)-associated retinal toxicity and vision loss are significant challenges, with a 2% prevalence in patients using HCQ for over 10 years and up…
Abstract Number: 1518 • ACR Convergence 2024
Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Maria Cuellar-Gutierrez¹, Jaime Flores Gouyonnet¹, Gabriel Figueroa-Parra², Marta Casal Moura¹, Fernando C. Fervenza¹, Andrew C. Hanson³, Cynthia Crowson¹, Sanjeev Sethi¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Mayo Clinic, Rochester
Background/Purpose: We aimed to assess the predictive value of the individual components of the NIH chronicity score and the Mayo Clinic Chronicity Score (MCCS) in…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].